Prescient Therapeutics Webcast Replay
- The exclusive and global licence agreement with The University of Pennsylvania (UPenn).
- An introduction to UPenn’s universal CAR-T Platform (OmniCAR) under licence to PTX.
- Updated the market regarding PTX’s licence, develop and collaborate business model towards personalised cancer therapies and improved patient outcomes.
Recorded on 26th May 2020 at 12pm (AEST).